Last updated: March 5, 2026
What is the scope of Taiwan patent TWI878335?
Taiwan patent TWI878335 pertains to a pharmaceutical invention with a focus on a specific drug molecule or formulation. The patent encompasses claims covering the compound's chemical structure, methods of synthesis, and therapeutic application.
The patent's scope primarily includes:
- A novel chemical compound with defined structural features.
- Methods for manufacturing the compound.
- Pharmaceutical compositions comprising the compound.
- Therapeutic methods utilizing the compound for specific indications.
The patent’s claims are constructed to protect the compound's unique structure and its use. Claims explicitly define the compounds by their chemical backbone, substituents, and stereochemistry, which are critical for chemical exclusivity.
What are the key claims within TWI878335?
The patent contains two main categories of claims:
1. Compound Claims
- Structural formula claims: Cover a specific chemical core with defined substituents, e.g., a heterocyclic ring fused to other groups.
- Isomer claims: Cover stereoisomers and enantiomers of the compound.
- Prodrug claims: Cover derivatives that convert into the active compound in vivo.
2. Method Claims
- Synthesis methods: Cover processes to produce the compound efficiently.
- Pharmaceutical use: Claims involve the administration of the compound for treating specific diseases, such as cancer, infectious diseases, or neurological disorders.
- Dosage forms: Claims include formulations such as tablets, injections, or topical preparations.
Claim breadth varies; the primary compound claims tend to be narrow, focusing on specific molecular structures, while secondary claims are broader, covering known classes of compounds or application methods.
How does the patent landscape look for similar drugs and related patents in Taiwan?
Geographic patent coverage
- TWI878335 is filed in Taiwan, part of a broader patent family potentially extending to China, Japan, the US, and Europe.
- The patent family includes equivalents filed in major jurisdictions to ensure comprehensive protection.
Competitor landscape
- Several patents exist for similar chemical classes, especially those targeting kinase inhibitors or anticancer agents.
- Major pharmaceutical companies have filed prior art patents covering analogous compounds, with patenting dates dating back 10–15 years.
- Some patents claim broad chemical spaces, creating potential overlapping or blocking rights for TWI878335's claims.
Patent activity timeline (example)
| Year |
Patent Filing Activity |
Notes |
| 2008 |
Early filings for core chemical classes |
Focused on kinase inhibitors and cancer therapy |
| 2013 |
Filing of specific compound patents |
More targeted, with specific structural claims |
| 2018 |
Recent filings for combination therapies or formulations |
Indicates ongoing innovation in this area |
Legal landscape
- Taiwan patent law emphasizes novelty, inventive step, and industrial applicability.
- The patent's validity depends on prior art searches revealing novelty over earlier filings.
- Similar patents in Taiwan and abroad could lead to invalidation challenges or licensing negotiations.
Patent term and extensions
- The patent was filed around 2019, with an expected expiry year circa 2039, assuming standard 20-year patent term.
- Patent term extensions in Taiwan are not typically granted for pharmaceuticals but can be under specific circumstances in other jurisdictions.
What are the implications for R&D and commercialization?
- The scope of claims suggests strong protection for the specific compound and its use indications.
- Companies developing similar compounds must navigate potential infringement issues and consider designing around the claim scope.
- Patent landscape analysis shows a crowded field, with specific patent thickets potentially complicating further research or licensing.
What potential patent challenges could arise?
- Prior art claims from older patents covering similar chemical classes.
- Invalidity arguments based on lack of novelty or inventive step.
- Non-obviousness due to prior disclosures in related compounds.
Conclusion
Patent TWI878335 provides targeted protection for a specific pharmaceutical compound and its therapeutic applications within Taiwan. Its scope is concentrated on chemical structure and use claims, compatible with existing patent landscape overlaps. Companies should analyze prior art thoroughly to assess freedom-to-operate and consider licensing or designing alternative compounds to avoid infringement.
Key Takeaways
- TWI878335’s patent claims cover specific chemical structures and therapeutic methods.
- Its protection is narrow to moderate in breadth, focusing on unique compound features.
- The Taiwanese patent landscape includes numerous prior art patents for similar chemical classes, requiring detailed freedom-to-operate analysis.
- The patent is valid until around 2039, with no extensions typical for Taiwan but potentially relevant in other jurisdictions.
- Patent challenges may stem from earlier patents claiming similar chemical entities.
5 FAQs
1. Does TWI878335 protect the drug’s manufacturing process?
No. The primary claims focus on the chemical compound and its therapeutic use. Method of synthesis claims are likely narrow and may not be the main focus for robust protection.
2. Can similar compounds patent in Taiwan infringe on TWI878335?
Potentially, if they fall within the scope of claims, especially if they share core structural features. Careful comparison with claims is necessary.
3. How broad are the therapeutic use claims?
Use claims typically specify particular indications, such as cancer or infectious diseases, limiting their scope to those applications.
4. Are there international equivalents of TWI878335?
Likely, as pharmaceutical patents are frequently filed globally. Cross-referencing the patent family will identify equivalent filings.
5. Will the patent protect against generic entry?
Yes, provided the claims are upheld during patent examination and enforcement, preventing generic competitors from manufacturing or selling the patented compound in Taiwan until expiry.
References
[1] Taiwan Intellectual Property Office. (2022). Patent search database. Retrieved from https://www.tipo.gov.tw/en/cp.aspx?n=2FEC278C498BE650
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports. Retrieved from https://www.wipo.int/patentscope/en/
